RINVOQ vs HUMIRA (adalimumab) in SELECT-SWITCH: what did the Week 12 comparison show?
Note: The page states superiority at Week 12 and shows the remission and low disease activity percentages only in charts, so no rates, differences, or p-values are quoted here. The Week 48 comparison was not controlled for multiplicity.